Navigation Links
Mindray Medical International Announces Third Quarter 2007 Results

ng activities and capital expenditures in the first nine months of 2007 were RMB417.6 million (US$55.7 million) and RMB165.3 million (US$22.1 million), respectively.

As of September 30, 2007 the company had 3,541 employees compared to 3,260 employees on June 30, 2007.

Business Outlook for Full Year 2007

The company maintains its full-year 2007 net revenue guidance range of RMB2,155 million to RMB2,185 million, representing annual growth of 42% to 44% over full fiscal year 2006.

The company also maintains its full-year 2007 non-GAAP net income guidance range of RMB600 million to RMB630 million, representing annual growth of 44% to 51% over full fiscal year 2006.

Non-GAAP net income per share is expected to be in the range of RMB5.31 to RMB5.58 on a fully diluted basis, assuming an estimated diluted share count of 113 million.

The company estimates its total share-based compensation expenses in 2007 will be approximately RMB60 million to RMB64 million based on the employee share options that have been granted as of November 1, 2007. This estimate is subject to the finalization of the option pricing model used to estimate the fair value of the options recently granted. Total expense and/or amortization of intangible assets related to the April 2006 acquisition of minority interest will be approximately RMB18.8 million in 2007.

The company expects its updated capital expenditure for 2007 to be in the range of RMB350 million to RMB400 million from the previous range of RMB400 million to RMB480 million.

The company's practice is to provide guidance on a full year basis only. This forecast reflects Mindray's current and preliminary views, which are subject to change.

Other Developments

Mr. Xu Hang, Mindray's chairman and co-chief executive officer and Mr. Li Xiting, Mindray's president and co-chief executive officer, have both recently entered into "10b5-1" selling plans to sell a portion of their shares according

SOURCE Mindray Medical International Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Barriers will not stop convergence of medical technologies
3. Medical College team creates website for tracking flu
4. Biomedical engineering conference invites manufacturers
5. Visions: Wade offers straight talk on e-medical records
6. Merge unveils updated medical imaging software
7. Medical College receives $1.4M cancer grant
8. Medical technology firm lands $100K federal grant
9. Doyle outlines spending for Medical College, UWM
10. And the winners in medical design are
11. Manufacturing partnership will move into biotech and biomedical spaces
Post Your Comments:
(Date:10/9/2015)...  Pulmatrix, Inc., (NASDAQ: PULM ) will be webcasting ... th Annual BIO Investor Forum on Tuesday, ... --> th Annual BIO Investor Forum ... pm EDT). --> Pulmatrix will be presenting ... on Thursday, October 15, 2015 at 8:30 am EDT. Additionally, ...
(Date:10/8/2015)... SAN DIEGO , Oct. 8, 2015 /PRNewswire/ ... oncology company developing new treatments for cancer and ... Chief Executive Officer, will be presenting at the ... Las Vegas :Event:Aegis Capital Corporation 2015 ... PDTLocation:Brahms 2 room, The Encore @ The Wynn ...
(Date:10/8/2015)... 2015 .   ... Goldman Small Cap Research, a stock market ... microcap sectors, announced today that it has published ... Inc. (OTCQB - PMCB), a publicly traded, clinical ... treatments for cancer and diabetes. To view the ...
(Date:10/8/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... the development of autologous cell therapies, today announced its schedule ... place in the month of October: Stem ... RepliCel will be presenting at the annual Partnering Forum, ... to be held October 7-9 in La ...
Breaking Biology Technology:
... sole U.S. supplier of 3M electrosurgical grounding pads ... ... Industries, Inc. and,3M Health Care announce an exclusive license and supply ... agreement,Medline has acquired the exclusive license and sales rights in the ...
... Eastern Time Today, GAITHERSBURG, Md., March 6 ... and corporate progress for,the full year ended December 31, ... further demonstrated that Iomai,s,vaccine and immunostimulant patches can be ... chief executive officer,of Iomai. "This lays the foundation for ...
... (Pink Sheets: VXGN), a biopharmaceutical company, today reported its,year ... a view to,ensuring that stockholders have the most current ... with Raven biotechnologies,inc. VaxGen,s Board of Directors has set ... of Stockholders to vote on the proposed merger., ...
Cached Biology Technology:
(Date:9/30/2015)... , Sept. 30, 2015  The global glucose monitoring device ... 2015. So says a new report on the industry from ... segment dominate the market, followed by continuous glucose monitoring and ... on the market for these products in its latest report, ... , ...
(Date:9/28/2015)... , Sept. 28, 2015 ... today that its expedited traveler service is ... platform transforms travel, bringing a frictionless experience, ... members. "CLEAR offers our travelers ... customer service," said Jim Smith , ...
(Date:9/28/2015)... , September 28, 2015 ... Component (Hardware & Software), Product (Scanner & Others), Application ... & Defense, & Others) & Geography Global - Forecast ... expected to reach USD 3627.90 Million by 2020, at ... Browse 65 market data T ables ...
Breaking Biology News(10 mins):
... and Nanosystems Research (IBN), Austrian Academy of Sciences ... of Technology, Cambridge, USA report the study of ... Designer Lipid-Like Peptide Surfactants” in the May 30th ... Their findings not only help us to ...
... a chronic and progressive lung disorder from which most patients ... by the insidious onset of dyspnea or cough and usually ... coworkers present in an article published in the online, open-access ... that a subset of IPF patients has a short duration ...
... chronic lung disease typically characterized by the slow but ... patients live about five years after diagnosis. However, according ... online journal PLoS ONE, a subset of patients with ... progression to complete pulmonary failure and death without a ...
Cached Biology News: